Robotics is one of the most visible innovations in orthopedics. Discussions usually focus on precision, digital navigation, reproducible surgical workflows and clinical outcomes. That perspective is important—but it shows only part of the change. I am equally interested in another question: what happens to industrial value creation when a surgical procedure becomes part of a digital and robotic system?
From an individual product to an integrated system
Robotics does not change only the procedure. It also changes the requirements for instruments, consumables, interfaces and product platforms.
In a robotic workflow, a saw blade is no longer simply a saw blade. A drill is no longer simply a drill. Instruments must fit mechanically, geometrically and functionally into a precisely defined process. Software, navigation, robotics, implants, instrumentation and consumables interact more closely.
This also changes the demands placed on development and manufacturing. Tolerances, interfaces and material properties can no longer be viewed only from the perspective of the individual product. What increasingly matters is how reliably that product performs within the complete system. Even a comparatively small component can have a significant impact on precision, process reliability and user experience.
A new competitive model is emerging
The competitive model in orthopedics is changing. Value increasingly lies not only in an individual product, but in the interaction of an entire ecosystem. A company that connects the relevant components, data and processes can shape a surgical workflow much more strongly than a supplier of isolated products.
This creates dependencies, but also new opportunities for differentiation. A successful system combines clinical performance with reliable technology, intuitive use, available instruments and a resilient supply of consumables.
Competition is therefore shifting from the individual product to the performance of the complete platform.
What do OEMs need to control themselves?
For OEMs, this creates a strategic question: which parts of the system must they control themselves, and where can specialized partners contribute additional capabilities?
Not every capability has to be built inside one company. What matters is understanding the critical interfaces and defining responsibility clearly across the system—from the functional connection between robotics and instrumentation to the translation of clinical requirements, critical manufacturing processes, validation, production scaling and lifecycle management.
The relevant decision is therefore not simply make or buy. It is which capabilities are strategically essential to control and advance the system.
The role of CDMOs is changing as well
A CDMO that only translates drawings into products may cover only a limited part of future value creation. A partner that understands how instruments and components function within a surgical system can become involved earlier—in development, design for manufacturing, industrialization and lifecycle management.
The value then comes from more than manufacturing capacity. It comes from connecting clinical requirements, technical interfaces, regulatory expectations and scalable production processes. The CDMO evolves from an executing supplier into an industrial development partner.
This view is consistent with current market developments. Roland Berger and William Blair identify robotics and orthopedics among the more dynamic areas of the MedTech C(D)MO market. They also observe that OEMs are concentrating spend on fewer, more capable partners and that integrated capabilities across the value chain are gaining relevance.
Robotics must also work economically
Another change is the migration of suitable procedures from traditional hospitals to ambulatory settings. Deloitte describes how technological advances, cost pressure and patient preferences support this shift, including for certain orthopedic procedures and patient groups.
This changes the economic assessment of robotic systems. An investment decision in a hospital may look different from one in an ambulatory surgery center. In addition to clinical performance, acquisition cost, utilization, space requirements, setup times, training effort and cost per procedure become particularly relevant.
Robotics must therefore meet three requirements at the same time: it must deliver clinically, make economic sense and remain industrially scalable. A technologically impressive system that is too complex or costly in daily use will not realize its full market potential.
From product competition to system competition
For me, this is one of the fundamental changes taking place in orthopedics. We are moving from competition between individual products to competition between complete surgical systems.
That changes how products are developed, industrialized and commercialized. It influences which capabilities OEMs need to build themselves and which partners will become strategically important over the long term.
Robotics is not only changing the operating room. It is reorganizing the orthopedic value chain. The companies that succeed will be those that understand how clinical requirements, digital technologies and industrial capabilities can be connected into a scalable system.
Robotics is shifting competition in orthopedics from individual products to complete surgical systems—and redefining which capabilities and partners create strategic value.